We profiled Æterna Zentaris (AEZS) stock as a highly speculative investment opportunity at around $.44. AEZS shares almost doubled in value for the last six weeks and still on their way to over a dollar. Market favored Æterna’s stock with Roth Capital initiation a “Buy” share/price target of $1.75 and even more price goal expectations from the […]
Profited On DARA BioSciences (DARA), Going Long On OXiGENE, Inc. (OXGN)
DARA BioSciences, Inc. (DARA) stock posted today 20.95% in gains on 6,424,094 shares in trading volume and brought to followers for about 55% in profits since our alert issued on September 13th. Our “gut feeling” and quick observation of DARA’s financials “told” us that a second offering for this biotech penny markets most likely is […]
KMAG, GTGP, SNMG, TWWI, AERN, ALTO, SRPX and more: SEC’s Order of Suspension of Trading
One simple question to you at first: why even bother to buy & hold OTC’s scam securities that can be halted by SEC at any time? Think… Anyways, here is the list of the 16 stocks that have been suspended for trading on September 17th: AER Energy Resources, Inc. (AERN) is a Nevada corporation based […]
WPCS International (WPCS): Financial Results for the 1st Quarter of the Fiscal Year 2013
WPCS International Incorporated (NASDAQ: WPCS) announced financial results for the fiscal year 2013 first quarter ended July 31, 2012 on Friday, September 14th, after market hours. Highlights: EBITDA of approximately $695,000 compared to an EBITDA loss of $7.1 million in preceding quarter ended April 30, 2012. Net income of approximately $994,000 or $0.14 per diluted […]
Generex Biotechnology Corporation (GNBT): Trading Alert
Generex Biotechnology Corporation (GNBT) announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients from its wholly owned subsidiary, Antigen Express, Inc. The results will be made at the 2012 ASCO (American Society of Clinical Oncology) Breast Cancer Symposium on September 14th. Dr. Elizabeth Mittendorf, the […]
DARA BioSciences (DARA): Granted Exclusive U.S. Commercial Rights to Gelclair®
DARA BioSciences, Inc. (DARA) announced today that company entered into an exclusive agreement with The Helsinn Group of Switzerland for U.S. commercial rights to Gelclair®. DARA plans to launch Gelclair, FDA-cleared product indicated for the treatment of oral mucositis, in the first quarter of 2013. Oral mucositis market is approximately 400,000 patients annually according to […]
Houston American Energy Corp. (HUSA): Unusual Volume Alert
Houston American Energy Corp. (NYSE: HUSA) shares ended a trading session with gains of over 29% and closed at the high of the day. HUSA has posted on the Company’s web site presentation slides reflecting site, seismic and geological data with respect to its holdings in the Serrania area in Colombia. Sophisticated investors were curious […]
Peregrine Pharmaceuticals (PPHM): Share Price Correction on the Way
By Mr. BiotechIll, Guest Author Shares of Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) gain almost half their value after announcement that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). At glance: Data show statistically significant improvement in overall survival for patients receiving […]
Quiksilver Inc. (ZQK): Third Quarter Profit Topped Estimates
Quiksilver Inc.’s (NYSE: ZQK) shares jumped today after the clothing company reported a third-quarter profit that topped estimates: Americas revenue increased 10% to $286.1 million from $260.2 million, and was up 12% in constant currency. Europe revenue decreased 13% to $154.1 million from $176.4 million, and was up modestly in constant currency. Asia Pacific revenue […]
Office Depot Inc. (ODP): Affirmed Full-Year 2012 Outlook
Office Depot Inc. (NYSE: ODP) shares gained 12% as of 11 AM EDT regardless of the “south” trading direction in overall retail sector. The office-supplies chain left unchanged its full-year 2012 outlook at a Goldman Sacks Global Retailing Conference: The Company expects to achieve full-year 2012 adjusted EBIT in the $125 to $135 million range, […]